AFT gains Australian registration for intravenous Maxigesic

Jenny Ruth
Tue, 23 Jul 2019

By Jenny Ruth July 24 (BusinessDesk) - AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration. The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution. The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, Sou...
Retail
NZ consumers still opening their wallets; govt's cut beats forecast
Rebecca Howard | Fri, 10 Jul 2020

A solid jump in retail spending and higher-than-forecast sales tax revenue point to consumers being in good heart. Seasonally adjusted retail card spending jumped 16.3 percent in June compared to M...

Election 2020
ELECTION 2020: Boag quits Nats; confirms more patient leaks
Victoria Young | Fri, 10 Jul 2020

Long time National Party member Michelle Boag has quit the organisation and admitted she sent patient details to opposition immigration spokesperson Michael Woodhouse.Woodhouse, in a statement, said h...

Primary Sector
Emissions, water settings will put brakes on export plans - economists
Brent Melville | Fri, 10 Jul 2020

Greenhouse gas commitments and freshwater settings have tempered New Zealand’s export goals for the next decade, which would otherwise be a whole lot more ambitious, economists say. The government'...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.

Sponsored: What’s next for the future of the office?

Think everyone is going to keep working from home? No so fast, says Milford Asset Management.